TY  - CONF
AU  - Biel, Davina
AU  - Steward, Anna
AU  - Dewenter, Anna
AU  - Dehsarvi, Amir
AU  - Zhu, Zeyu
AU  - Roemer-Cassiano, Sebastian
AU  - Frontzkowski, Lukas
AU  - Hirsch, Fabian
AU  - Brendel, Matthias
AU  - Franzmeier, Nicolai
TI  - Plasma p‐tau217 as a suitable biomarker for monitoring cognitive changes in Alzheimer’s disease
JO  - Alzheimer's and dementia
VL  - 21
IS  - Suppl 8
SN  - 1552-5260
M1  - DZNE-2025-01502
SP  - e110180
PY  - 2025
AB  - With the approval of anti-amyloid therapies in Alzheimer's disease (AD), surrogate biomarkers are urgently needed to monitor treatment effects that translate into clinical benefits. Candidate biomarkers, including amyloid-PET, tau-PET, plasma phosphorylated tau (p-tau), and MRI-assessed atrophy, capture core pathophysiological changes in AD. While cross-sectional biomarker assessments are critical for diagnosis and staging, biomarker change rates may better reflect disease dynamics, making them more suitable for monitoring treatment efficacy. Therefore, we determined which biomarker most effectively tracks cognitive changes in AD, identifying those best suited for efficient monitoring of disease-modifying treatments.We leveraged ADNI (N = 108) and A4 (N = 151) participants with longitudinal AD biomarker data (global amyloid-PET, temporal meta tau-PET, plasma p-tau217, MRI-assessed cortical thickness in the AD signature region) together with cognitive assessments (ADNI: MMSE, ADAS13, CDR-SB; A4: MMSE, PACC). Linear mixed models were used to calculate change rates for biomarkers and cognition. To test whether biomarker changes track cognitive decline, linear models were applied, to test biomarker change rates as a predictor of cognitive change rates. Standardized beta values from bootstrapped linear models were extracted to compare the strengths of correlations between biomarkers and cognitive decline. For non-parametric comparisons, 95
T2  - Alzheimer’s Association International Conference
CY  - 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2  - 27 Jul 2025 - 31 Jul 2025
M2  - Toronto, Canada
KW  - Humans
KW  - Alzheimer Disease: diagnostic imaging
KW  - Alzheimer Disease: pathology
KW  - Male
KW  - Female
KW  - tau Proteins: blood
KW  - Biomarkers: blood
KW  - Aged
KW  - Magnetic Resonance Imaging
KW  - Positron-Emission Tomography
KW  - Longitudinal Studies
KW  - Aged, 80 and over
KW  - Brain: diagnostic imaging
KW  - Brain: pathology
KW  - Amyloid beta-Peptides
KW  - tau Proteins (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Amyloid beta-Peptides (NLM Chemicals)
LB  - PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
C6  - pmid:41433469
C2  - pmc:PMC12725594
DO  - DOI:10.1002/alz70862_110180
UR  - https://pub.dzne.de/record/283095
ER  -